This biomarker study has been designed to assess the effects of different agents in both
tumour tissue and peripheral samples to help inform the best combinations of DDR agents with
immuno-oncology (IO) therapies. In the first instance 2 DDR agents will be assessed
separately as monotherapy. Additional arms may be added later to evaluate other DDR agents
and/or DDR and immunotherapy agents in combination or in sequence. The primary objective of
the study is to investigate immune activation due to DDR inhibition by assessing tumour and
blood samples of patients treated with study investigational agent(s).